Fusion Antibodies shares slid to a new 52-week low after the Belfast antibody specialist reported sharply lower first-half revenue, a much thinner gross margin and cash of £135k at the end of September.

Shares in Fusion Antibodies (LSE:FAB) fell sharply on 15 October 2026 after the company published its AGM statement, including an H1 trading and R&D update, at 07:00 ahead of its annual general meeting. The update showed that unaudited revenue for the first half of its FY27 financial year (H1 FY27) was approximately £457k, compared with £838k in the same period a year earlier, while unaudited gross margin dropped to 10% from 30%. The company also disclosed cash of £135k at 30 September 2026 and said the Board is reviewing its working capital requirements.

Investors reacted quickly. The shares closed at 5.75p, down 4.00p or 41.03% from the previous close of 9.75p, after touching an intraday low of 4.85p, a new 52-week low. Volume reached 7,924,416 shares, and the move left the company with a market capitalisation of £7.20m. Fusion is one of the stocks drawing heavy discussion among UK investors today, with the combination of weaker trading and a tight cash position at the centre of attention.

The AGM trading update in detail

The AGM statement painted a difficult picture for the first half. Simon Douglas, Chairman, said that "difficult market conditions have affected first half trading." Revenue for the full FY26 year had been £2.11m, so the first-half figure of approximately £457k represents a marked slowdown in activity. Gross margin also fell to 10%, from 30% a year earlier.

Key figures from the update include:

  • H1 FY27 unaudited revenue: approximately £457k (H1 FY26: £838k)
  • Unaudited gross margin: 10% (H1 FY26: 30%)
  • Cash at 30 September 2026: £135k (30 September 2025: £251k)
  • Grant funding due "in the next few weeks": more than £100k

In response, the company has introduced cost reduction measures, including a temporary recruitment freeze. The Chairman also said: "The Board is actively reviewing the Company's working capital requirements", and the company indicated that a further update would be provided "as appropriate". No date has been given for that update, and the interim results date has not been announced.

The AGM itself was held at 11.00 a.m. on Thursday 15 October 2026 at the company's premises on Springbank Road in Belfast.

Scientific progress offers a partial offset

Alongside the trading figures, the company gave an update on its R&D programmes. In the first in vivo study of its DR5 programme, carried out in mice with human colorectal cancer cells, two of the four antibody formats tested produced a significant reduction in the rate of tumour growth. The company said this result was comparable to the positive control, conatumumab. A second dose-response study is planned.

The DR5 project is supported by an InnovateUK Launchpad grant with Queen's University Belfast worth over £808K in total, of which up to £545K is direct non-dilutive funding to Fusion. In June, the company said the project's completion date had been extended from 31 October 2026 to 31 December 2026. At that time, Richard Buick, Chief Scientific Officer, said the latest variants had shown clear activity in induced cancer cell death assays.

On its OptiMAL® platform, the company said a further agreement with the NCI is under negotiation, although the timing remains uncertain. Separately, in August the company announced acceptance of its Australian patent application no. 2019365135, "Antibody Library and Method", with the grant following administrative steps, including a three-month gazetting period.

The business at a glance

Fusion (LSE:FAB) is a contract antibody services business based in Belfast, spun out of Queen's University Belfast in 2001. It provides antibody discovery, engineering and humanisation services, including its CDRx® offering. Its OptiMAL® and "Opti" libraries are patented in the US, Japan and Canada, with acceptance now received in Australia. The company's shares were admitted to AIM on 18 December 2017.

Because much of its revenue is project-based, results can vary considerably from period to period. That variability was evident in the contrast between the latest half-year update and the full-year results published in September.

How the latest numbers compare with the full year

Fusion's Final Results for the year to 31 March 2026, originally released on 14 September 2026 and replaced on 15 September 2026 to correct the gross margin to 58.3%, showed revenue of £2,110k, up from £1,965k. The operating loss narrowed to £1,133k from a restated £1,628k, and the loss after tax was £1,149k compared with a restated £1,626k. Basic loss per share was (1.2) pence. Year-end cash stood at £1,043k, up from £359k, and net assets were £1,622k.

At the time, Adrian Kinkaid, Chief Executive Officer, said: "I am particularly encouraged by the improvement in our service revenues during the second half". However, the Chairman also warned in that announcement that conditions were "adversely impacting Fusion's performance in H1 of FY27."

The year-end cash figure was supported by a placing and subscription on 27 January 2026, which raised c.£1.4m gross through the issue of 11,056,905 shares at 13 pence. By 30 September 2026, cash had fallen to £135k.

Risks to weigh

The update brings several risks into sharper focus:

  • Going concern and funding: the FY26 accounts include a material uncertainty in the going concern note, stating that additional funding "is expected to be required" and is not contractually committed. Cash was £135k at 30 September 2026, and the working capital review is ongoing.
  • Dilution: any new share issue could dilute existing shareholders. The January 2026 raise was priced at 13p, compared with the current 5.75p.
  • Trading: first-half revenue roughly halved and gross margin fell to 10%. Revenue is project-based and can be variable.
  • Execution: the timing of any new NCI agreement is uncertain, and the DR5 programme remains at a pre-clinical stage.

More than £100k of grant funding is expected in the coming weeks, but investors will be looking for clarity on how the Board intends to address its working capital position.

What to watch next

There are several near-term points of interest for shareholders:

  • Receipt of the grant funding the company says is due in the next few weeks
  • Any further update from the Board's working capital review
  • Progress on the second DR5 dose-response study
  • News on the OptiMAL® negotiations with the NCI
  • Confirmation of the interim results date, which has not yet been announced

The shares have now fallen from a 52-week high of 19.75p, set on 12 December 2025, to today's low of 4.85p. The sharp reaction to the AGM update reflects how closely investors are watching Fusion's funding position, and the next announcement on working capital is likely to be a key moment for the company.